Company: scPharmaceuticals, Inc.
Symbol: SCPH
Description: They are a pharmaceutical company focused on developing and commercializing products that have the potential to transform the way therapy is delivered, advance patient care and reduce healthcare costs.
Shares: 6.4 million
Price Range: $14.00-$16.00
Trade Date: 11/17
Underwriter(s): Jefferies, Leerink, BMO Capital Markets
Terms Added: 11-7-17
Business: Their proprietary platform is designed to enable the subcutaneous administration of therapies that have previously been limited to intravenous, or IV, delivery. By moving delivery away from the high-cost healthcare settings typically required for IV administration, they believe their technology reduces overall healthcare costs and advances the quality and convenience of care. Their lead product candidate, Furoscix, consists of their subcutaneous formulation of furosemide delivered via our patented sc2Wear Infusor and is under development for treatment of worsening, or decompensated, heart failure outside of the inpatient setting. They filed a new drug application, or NDA, for Furoscix, with the U.S. Food and Drug Administration, or FDA, in August 2017. The FDA notified us in October 2017 that it had accepted their NDA for review and assigned them a June 23, 2018 Prescription Drug User Fee Act, or PDUFA, date which is the goal date for the FDA to complete its review of their NDA.
Insider Buying: Certain of their existing shareholders, including certain of their directors and affiliates of their directors, and their affiliated entities have indicated an interest in purchasing an aggregate of up to approximately $35.0 million of their common shares in this offering at the initial public offering price per share.
Healthcare IPOs in 2017 – How the sector has performed as of 11.10.17 intraday
Book-Building Status: The way the book comes together during the week of the roadshow is the bkost critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, we have our latest performance results with commentary from the month of May by clicking here.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish